title: Presence of anti-phosphatidylserine-prothrombin complex antibodies and anti-moesin antibodies in patients with polyarteritis nodosa.
abstract: We measured both serum anti-phosphatidylserine-prothrombin complex (anti-PSPT) antibodies and anti-moesin antibodies, as well as various cytokines (interleukin [IL]-2, IL-4, IL-5, IL-10, IL-13, IL-17, granulocyte macrophage colony-stimulating factor, γ-interferon, tumor necrosis factor-α) levels in polyarteritis nodosa (PAN) patients with cutaneous manifestations. All patients showed the presence of a histological necrotizing vasculitis in the skin specimen. They were treated with i.v. cyclophosphamide pulse therapy (IV-CY) and prednisolone therapy or steroid pulse therapy. The immunological assessments were performed on sera collected prior to and after treatment with IV-CY or steroid pulse therapy. We found a significant positive correlation between serum anti-moesin antibodies and both clinical Birmingham Vasculitis Activity Scores and Vasculitis Damage Index. Anti-PSPT antibody and IL-2 levels after treatment in PAN patients were significantly lower than before treatment. In contrast, anti-moesin antibody levels were higher following IV-CY or steroid pulse therapy compared with the pretreatment levels. In the treatment-resistant PAN patients (n = 8), anti-PSPT antibody levels after treatment were significantly lower than before treatment. In contrast, anti-moesin antibody levels after treatment in the patients were significantly higher compared with the pretreatment levels. Immunohistochemical staining revealed moesin overexpression in mainly fibrinoid necrosis of the affected arteries in the PAN patients. We suggest that measurement of serum anti-PSPT antibody levels could serve as a marker for PAN and aid in earlier diagnosis of PAN. We also propose that elevated serum anti-moesin antibodies could play some role of the exacerbation in patients with PAN.
authors.affiliation: Department of Dermatology, St Marianna University School of Medicine, Kawasaki, Japan.
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Okano
authors.affiliation: Department of Dermatology, St Marianna University School of Medicine, Kawasaki, Japan.
authors.forename: Sora
authors.initials: S
authors.lastname: Takeuchi
authors.affiliation: Department of Dermatology, St Marianna University School of Medicine, Kawasaki, Japan.
authors.forename: Yoshinao
authors.initials: Y
authors.lastname: Soma
authors.affiliation: Laboratory of Biological Science and Laboratory of Biosciences, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan.
authors.forename: Koya
authors.initials: K
authors.lastname: Suzuki
authors.affiliation: Laboratory of Biological Science and Laboratory of Biosciences, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan.
authors.forename: Sachiko
authors.initials: S
authors.lastname: Tsukita
authors.affiliation: Department of Pathology/Pathophysiology, Division of Pathophysiological Science, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Ishizu
authors.affiliation: Department of Health Protection, Graduate School of Medicine, Teikyo University Asia International Institute of Infectious Disease Control, Tokyo, Japan.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Suzuki
authors.affiliation: Department of Dermatology, St Marianna University School of Medicine, Kawasaki, Japan.
authors.forename: Tamihiro
authors.initials: T
authors.lastname: Kawakami
mesh_terms: D061605:Administration, Intravenous; D000328:Adult; D000906:Antibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D016207:Cytokines / Q000097:blood; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008840:Microfilament Proteins / Q000276:immunology* / Q000378:metabolism; D008875:Middle Aged; D010718:Phosphatidylserines / Q000276:immunology*; D010488:Polyarteritis Nodosa / Q000097:blood* / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D011516:Prothrombin / Q000276:immunology*; D020551:Pulse Therapy, Drug; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D015415:Biomarkers; D016207:Cytokines; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D008840:Microfilament Proteins; D010718:Phosphatidylserines; C071058:moesin; D003520:Cyclophosphamide; D011516:Prothrombin; D011239:Prednisolone
keywords: anti-moesin antibodies; anti-phosphatidylserine-prothrombin complex antibodies; cutaneous manifestations; moesin; polyarteritis nodosa